Eli Lilly drug bimagrumab saves muscle mass when added to Novo’s Wegovy

Posted on by wpadmin
Eli Lilly and Company World Headquarters. Lilly makes Medicines and Pharmaceuticals.

jetcityimage

  • New phase 2 data on Eli Lilly’s (NYSE:LLY) experimental bimagrumab showed that when combined with Novo Nordisk’s (NVO) GLP-1 for weight loss, Wegovy (semaglutide), led to preservation of muscle mass while achieving significant weight loss.
  • The data found that patients

Leave a Reply

Your email address will not be published. Required fields are marked *